Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Clinical evidence

EMBARQ-CSU1

52 evidence topics · 7 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Secondary outcome measures in the current ClinicalTrials.gov record

“Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)” (opens the source at this quote in a new tab)

“The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)” (opens the source at this quote in a new tab)

“The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Percentage of participants with UAS7 = 0 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12” (opens the source at this quote in a new tab)

“Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.” (opens the source at this quote in a new tab)

“Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)

“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
CharacteristicPlacebo every 4 weeks (N=325)Barzolvolimab 150 mg every 4 weeks (N=320)Barzolvolimab 300 mg every 8 weeks (N=318)
Age (years), mean (SD)“46.4 (14.58)”“46.1 (14.49)”“47.0 (14.7)”
Female, n (%)“235 (72.3)”“243 (75.9)”“228 (71.7)”
Race, White, n (%)“228 (70.2)”“233 (72.8)”“216 (67.9)”
Race, Black, n (%)“35 (10.8)”“39 (12.2)”“31 (9.7)”
Race, Asian, n (%)“40 (12.3)”“30 (9.4)”“47 (14.8)”
Weight (kg), mean (SD)“79.9 (20.47)”“79.39 (16.98)”“78.34 (18.06)”
UAS7 score, mean (SD)“30.9 (7.32)”“30.6 (7.44)”“30.3 (7.01)”
Severe disease (UAS7 of 28 or more), n (%)“216 (66.5)”“213 (66.6)”“216 (67.9)”
Omalizumab refractory, n (%)“55 (16.9)”“52 (16.3)”“52 (16.4)”
AAS7 greater than 0, n (%)“237 (72.9)”“238 (74.4)”“239 (75.2)”
AAS7 in participants with AAS7 greater than 0, mean (SD)“57.1 (29.99)”“52.0 (29.15)”“54.9 (28.24)”
DLQI score, mean (SD)“16.0 (7.34)”“15.5 (7.13)”“15.6 (7.13)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Event, N (%)Placebo every 4 weeks (N=645)Barzolvolimab 150 mg every 4 weeks (N=648)Barzolvolimab 300 mg every 8 weeks (N=641)
Participants with at least 1 adverse event“340 (52.7)”“490 (75.6)”“492 (76.8)”
Hair color changes“29 (4.5)”“292 (45.1)”“330 (51.5)”
Skin hypopigmentation“16 (2.5)”“71 (11.0)”“64 (10.0)”
Neutropenia“4 (0.6)”“59 (9.1)”“75 (11.7)”
Skin hyperpigmentation“5 (0.8)”“59 (9.1)”“58 (9.1)”
Dysgeusia“9 (1.4)”“44 (6.8)”“63 (9.8)”
Hypogeusia“10 (1.6)”“33 (5.1)”“53 (8.3)”
Nasopharyngitis“36 (5.6)”“41 (6.3)”“40 (6.2)”
Anemia“4 (0.6)”“20 (3.1)”“20 (3.1)”
Participants with serious adverse events“15 (2.3)”“6 (0.9)”“14 (2.2)”
Treatment-related serious adverse events“1 (0.2)”“3 (0.5)”“4 (0.6)”
Anaphylaxis adjudicated as probable (grade 4)“0”“2”“1 (occurred after placebo dose)”
Anaphylaxis, other“1A”“1B”“3C”
Study limitations
Summary: limitations of the available EMBARQ-CSU1 evidence
  • Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
  • The record history comparing version 1 (2024-05-31) with version 18 (2026-02-12) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (15.4%, 49.0%, and 45.1%) are presented by the company, which cites the importance of complete response to patients and physicians.
  • Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
  • Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24. The sources state the placebo duration differently: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”.
  • Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
  • Baseline DLQI is reported (mean 16.0, 15.5, and 15.6), but no DLQI or other health-related quality of life result after baseline is reported.
  • The omalizumab-refractory subpopulation comprised 55, 52, and 52 participants (16.9%, 16.3%, and 16.4% of each arm). The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.